Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

NCT04665739 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04665739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
February 3, 2023
Completion date
July 1, 2027
Enrollment
70 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung neuroendocrine tumor, functioning lung neuroendocrine tumor, locally advanced lung neuroendocrine neoplasm, lung neuroendocrine neoplasm, lung neuroendocrine tumor g1, lung neuroendocrine tumor g2, metastatic lung neuroendocrine neoplasm, metastatic lung neuroendocrine tumor, non-functioning lung neuroendocrine tumor, recurrent lung neuroendocrine neoplasm, unresectable lung neuroendocrine neoplasm, unresectable lung neuroendocrine tumor